Belzutifan/MK-6482 in PNET + PPGL + VHL

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

CLINICALTRIALS.GOV IDENTIFIER: NCT04924075

DRUG/TREATMENT: Oral Treatment: Belzutifan 

PHASE: 2

STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC

Update (May 14, 2025): Based on results from this study, the FDA approved belzutifan (Welireg) for patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This is the first oral therapy approved for PPGL and represents an important new treatment option. Read the FDA announcement →

Dr. Hendifar Discusses Belzutifan in PNET + PPGL + VHL

DESCRIPTION: 

Merck is sponsoring a phase 2 trial for those with pheochromocytoma/paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) who have progressed in the past 12 months. Those with pNET must have experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus or sunitinib. Belzutifan is a daily, oral medication currently approved for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. 

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Merck Sharp & Dohme LLC

EMAIL: Trialsites@merck.com 

PHONE: 1-888-577-8839

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.